Ed Seguine CEO of Clinical Ink Talks About Hybrid Clinical Trials During and Post COVID-19
Ed Seguine, CEO of Clinical Ink, talks about how hybrid trials, BYOD ePRO, and DDC can provide a valuable solution during a healthcare crisis like COVID-19
You can learn more about Ed Seguine and Clinical Ink below: https://www.clinicalink.com/virtual-trials/
Create your
podcast in
minutes
It is Free